Ontology highlight
ABSTRACT:
SUBMITTER: Wang JQ
PROVIDER: S-EPMC7072352 | biostudies-literature | 2020 Feb
REPOSITORIES: biostudies-literature
Wang Jing-Quan JQ Li Jonathan Y JY Teng Qiu-Xu QX Lei Zi-Ning ZN Ji Ning N Cui Qingbin Q Zeng Leli L Pan Yihang Y Yang Dong-Hua DH Chen Zhe-Sheng ZS
Cancers 20200218 2
Previous studies have shown that small-molecule BCL-2 inhibitors can have a synergistic interaction with ABCG2 substrates in chemotherapy. Venetoclax is a potent and selective BCL-2 inhibitor, approved by the FDA in 2016 for the treatment of patients with chronic lymphocytic leukemia (CLL). This study showed that, at a non-toxic concentration, venetoclax at 10 µM significantly reversed multidrug resistance (MDR) mediated by wild-type ABCG2, without significantly affecting MDR mediated by mutated ...[more]